Belarus registers Sputnik V anti-COVID-19 vaccine for domestic production – RDIF
<p> MINSK, Dec 21 - PrimePress. Belarus is the first country to register the Russian Sputnik V anti-COVID-19 vaccine. Its localization is in progress, the Russian Direct Investment Fund (RDIF) reports. </p> <p> </p> <p> “The Health Ministry of Belarus has issued a registration certificate for the Russian Sputnik V anti-coronavirus vaccine,” reads the report. </p> <p> </p> <p> Vaccination of volunteers in Belarus began on October 1, 2020 as part of randomized double blind placebo control studies of Sputnik V sponsored by the RDIF. It involved 100 volunteers at eight medical institutions that have been selected to operate as research centers. </p> <p> </p> <p> “The registration of the vaccine in Belarus and its localization will significantly scale up the vaccination of the population,” says RDIF CEO Kirill Dmitriev. </p> <p> </p> <p> Sputnik V was designed by Russian Gamaleya Research Institute of Epidemiology and Microbiology for COVID-19 prophylaxis. </p> <p> </p> <p> According to President of Belarus Alexander Lukashenko, development of Belarus’ own anti-coronavirus vaccine may cost 5 million Belarusian rubles ($2 million at the rate of the National Bank of Belarus). He said three main options were under consideration: purchase of Russian vaccines, organization of vaccine production from the Russian strain in Belarus, and development of Belarus’ own vaccine. End </p>
2020-12-22
Primepress
MINSK, Dec 21 - PrimePress. Belarus is the first country to register the Russian Sputnik V anti-COVID-19 vaccine. Its localization is in progress, the Russian Direct Investment Fund (RDIF) reports.
“The Health Ministry of Belarus has issued a registration certificate for the Russian Sputnik V anti-coronavirus vaccine,” reads the report.
Vaccination of volunteers in Belarus began on October 1, 2020 as part of randomized double blind placebo control studies of Sputnik V sponsored by the RDIF. It involved 100 volunteers at eight medical institutions that have been selected to operate as research centers.
“The registration of the vaccine in Belarus and its localization will significantly scale up the vaccination of the population,” says RDIF CEO Kirill Dmitriev.
Sputnik V was designed by Russian Gamaleya Research Institute of Epidemiology and Microbiology for COVID-19 prophylaxis.
According to President of Belarus Alexander Lukashenko, development of Belarus’ own anti-coronavirus vaccine may cost 5 million Belarusian rubles ($2 million at the rate of the National Bank of Belarus). He said three main options were under consideration: purchase of Russian vaccines, organization of vaccine production from the Russian strain in Belarus, and development of Belarus’ own vaccine. End